Characterization and Quantification of Motor Speech Disorders in Huntington's Disease: Identification of Acoustic Markers (TPMH)

The study proposes to identify deviant speech dimensions in patients with HD at presymptomatic and declared stages of the disease, compared to healthy subjects, using the computerized MonPaGe speech protocol. This tool is based on a multidimensional and quantified assessment of voice and speech, by a set of targeted acoustic and perceptual criteria.

Study Overview

• Status: Completed
• Conditions: Huntington Disease
• Intervention / Treatment: Other: Speech evaluation with the clinical evaluation of dysarthria; Other: complete assessment of the MonPaGe computerized protocol

Detailed Description

Huntington's disease (HD) is a neurodegenerative disorder of the central nervous system, of genetic etiology. It manifests itself in motor, cognitive and psychiatric disorders, which progressively worsen until the patient is grabbed. Motor speech performance disorders are present from the early stage of the disease. These difficulties, which progressively worsen until the end of the patient's life, lead to a communication disorder and constitute a major handicap with social withdrawal, loss of self-esteem and isolation, which are always very painfully experienced by patients and their entourage. Dysarthria in the HD has been very little studied, which makes its speech therapy uncodified. According to the most widely used classification by speech therapists and neurologists, the Darley classification (1975), the speech disorders observed in the HD are included in the heterogeneous group of hyperkinetic dysarthria, whose contours and properties are ill-defined. In this context, a more precise knowledge of speech disorders in the HD appears necessary to identify and characterize the different types of dysarthria and the dysfunctions associated with each level of production (respiration, phonation, resonance, articulation, prosody) and thus improve speech language therapy.

The investigators propose to use an acoustic evaluation to support the perceptual evaluation, available in the MonPaGe protocol, to describe the fine characteristics of the speech disorders in the HD and to define objective markers of dysarthria in this disease for francophone patients.

Each patient is seen in the framework of his annual follow-up consultation in the Competence Center mdH of Bordeaux University Hospital or in the Reference Center mdH of the hospital Henri Mondor of Créteil, for an evaluation of his speech with the computerized tool MonPaGe. A first speech evaluation with the BECD (Auzou, 2006) during 30 minutes is proposed to exclude very severe dysarthria. At the end of this rapid test subtest, the subjects who obtain a perceptive score <16 are offered the complete assesment of the MonPaGe computerized protocol (30 minutes).The application records directly and anonymously stores speech productions made by the patient.The productions are transmitted to the Phonetics and Phonology Laboratory of Paris (UMR 7018 CNRS / Sorbonne Nouvelle), via a secure large data exchange server and are subject to a perceptual and acoustic evaluation a posteriori.

• Study Type: Observational
• Enrollment (Actual): 150

Contacts and Locations

• Study Contact: Name: Sonia FRAISSE; Phone Number: 05 56 79 59 52; Email: sonia.fraisse@chu-bordeaux.fr

Study Locations

• France
  • Créteil, France
    • Hopital Henri-Mondor
  • Talence, France
    • Centre Hospitalier Universitaire de Bordeaux

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

patients with Huntington's disease at presymptomatic and declared stages of the disease.

Description

Inclusion Criteria:

• major patients
• francophone patients
• Huntington's disease carriers confirmed by molecular biological analysis
• carriers of pre-symptomatic Huntington's disease: Total Motor Score of the Unified Huntington's Disease Rating Scale <5
• carriers of Huntington's disease at a declared stage: Total Motor Score of the Unified Huntington's Disease Rating Scale ≥ 5
• followed in the Competence Center Huntington's disease Bordeaux Hospital or in the Reference Center Huntington's disease Henri Mondor Hospital of Créteil
• affiliates or beneficiaries of a social security scheme
• Finally, a free, informed and express consent of the patient must be collected.

Exclusion Criteria:

• Huntington's disease patients with severe dysarthria (BECD score> 16), acoustic analysis not being possible on unintelligible speech
• patients placed under the protection of justice

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients with Huntington's disease; Each patient is seen in the framework of his annual follow-up consultation, for an evaluation of his speech with the computerized tool MonPaGe.	Other: Speech evaluation with the clinical evaluation of dysarthria; A first speech evaluation with the clinical evaluation of dysarthria during 30 minutes is proposed to exclude very severe dysarthria.; Other: complete assessment of the MonPaGe computerized protocol; The application records directly and anonymously stores speech productions made by the patient.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Determination of the intelligibility score.	Defined as the number of words correctly recognized by the evaluator (score out of 15).	Day 1
Determination of the maximum phonation time.	Expressed in milliseconds.	Day 1
Determination of the phonation characteristics.	Described as the mean and standard deviation of fundamental frequency (in Hz),	Day 1
Determination of the intensity modulation capacities.	Based on a scale of 0 to 4.	Day 1
Determination of the Coarticulation.	Expressed in Hz. Extracted from the spectral properties of the acoustic signal of certain words.	Day 1
Determination of the prosody.	assessed on a scale 0 to 4 on particular sentences.	Day 1
Determination of the diadocokinesies,	assessed on two scales: precision (0 to 4) and control (0 to 4).	Day 1
Determination of the articulation rate.	expressed in syllabs per second.	Day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Determination of the Huntington's disease stage.	The Huntington's disease stage will be determined based on the Total Functional Capacity (TFC) and the Total Motor Score (TMS) scales of the Unified Huntington's Disease Rating Scale: pre-symptomatic stage: TFC = 13 / TMS <5; light stage: TFC ≥11 / TMS 5 to 20; moderate stage: TFC = 7 to 10 / TMS: 20 to 40	Day 1
Determination of the clinical motor forms of the Huntington's disease.	The clinical motor forms of Huntington disease will be determined by the motor UHDRS scale (Total Motor Score), which evaluates oculomotricity, skill and manual planning, bradykinesia, dystonia and rigidity, chorea and walking, balance, lingual protrusion and dysarthria.	Day 1
Determination of the level of cognitive impairment	The level of cognitive impairment will be assessed by the cognitive score as per the Unified Huntington's Disease Rating Scale.	Day 1

Collaborators and Investigators

• Sponsor: University Hospital, Bordeaux
• Collaborators: Centre National de la Recherche Scientifique, France

Study record dates

Study Major Dates

• Study Start (Actual): February 23, 2021
• Primary Completion (Actual): February 5, 2024
• Study Completion (Actual): February 5, 2024

Study Registration Dates

• First Submitted: November 1, 2020
• First Submitted That Met QC Criteria: November 13, 2020
• First Posted (Actual): November 16, 2020

Study Record Updates

• Last Update Posted (Actual): February 20, 2024
• Last Update Submitted That Met QC Criteria: February 16, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: Dysarthria; Huntington's disease; Motor speech performance; Acoustic markers
• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Neurocognitive Disorders; Genetic Diseases, Inborn; Basal Ganglia Diseases; Movement Disorders; Neurodegenerative Diseases; Dyskinesias; Heredodegenerative Disorders, Nervous System; Dementia; Cognition Disorders; Language Disorders; Communication Disorders; Chorea; Huntington Disease; Speech Disorders
• Other Study ID Numbers: CHUBX 2018/67

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No